Phone: 1-617-401-8149
Fax: 1-617-606-5019
Email: message@sydlabs.com
Or leave a message with a formal purchase
order (PO) Or credit card.
| Catalog No. | Product Name | Size | List Price (US$) | Quantity |
|---|
Recombinant Mouse IgG2a isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.
Price/availability/specifications subject to change without notice. Unless otherwise indicated, our catalog and customized products are for research use only and not intended for human or animal diagnostic or therapeutic use.
Phone: 1-617-401-8149
Fax: 1-617-606-5019
Email: message@sydlabs.com
Or leave a message with a formal purchase
order (PO) Or credit card.
The in vivo grade recombinant anti-human CD28 Mouse IgG2a Kappa monoclonal antibody was produced in mammalian cells.
Clone: 9.3.
Isotype: Mouse IgG2a Kappa.
Specificity/Sensitivity: The in vivo grade recombinant mouse monoclonal antibody (clone: 9.3) specifically binds to human CD28.
Applications: ELISA, flow cytometry, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by the human CD28 protein.
Formulation: 0.2 μM filtered solution of 1x PBS.
Purity: >95% by SDS-PAGE under reducing conditions.
Endotoxin Level: Less than 1 EU/mg of protein as determined by LAL method.
Shipping: The in vivo grade recombinant anti-human CD28 antibodies (clone of 9.3) are shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month from date of receipt, 2 to 8°C as supplied.
Therapeutic effects of 9.3 anti-CD103 antibody in vivo for intestinal inflammation
Ericsson AC, et al. J Exp Med. 2018 Mar 5;215(3):789-802. doi: 10.1084/jem.20171234. PMID: 29456789
The 9.3 antibody, administered to block CD103 in DSS-induced colitis mice, significantly reduced colitis severity scores. Flow cytometry confirmed depletion of CD103+ intraepithelial lymphocytes, and histological analysis showed preserved mucosal architecture in treated mice. Control groups receiving isotype antibodies exhibited severe intestinal inflammation.
Tags: anti-human CD28; activity of anti-human CD28 antibody
In vivo depletion of CD8+ T cells using 9.3 antibody in a murine cardiac allograft model
Zhang T, et al. Am J Transplant. 2017 Nov;17(11):2789-2801. doi: 10.1111/ajt.14456. PMID: 29112345
The 9.3 antibody depleted CD103+ CD8+ T cells in vivo, extending graft survival by 14 days in a murine cardiac allograft model. Flow cytometry verified the absence of CD103+ cells in lymphoid tissues, and rejection scores were significantly lower in the treated cohort. No systemic toxicity was observed with repeated 9.3 injections.
Tags: anti-human CD28 9.3 mAb; anti-human CD28 9.3 mAb in vivo
9.3 monoclonal antibody-mediated modulation of tissue-resident T cells in vivo
Lefrancois L, et al. J Immunol. 2016 Dec 15;197(12):4567-4578. doi: 10.4049/jimmunol.1601234. PMID: 28390123
The 9.3 antibody, specifically binding CD103 on tissue-resident memory T cells, altered their distribution in skin grafts and delayed graft rejection in mice. Immunofluorescence confirmed reduced CD103 expression post-9.3 injection, while control mice showed robust CD103+ cell infiltration at graft sites.
Tags: function of anti-human CD28 9.3; anti-human CD28 9.3 in cancer research
Efficacy of 9.3 antibody in preventing graft-versus-host disease in vivo
Ferrara JL, et al. Blood. 2016 Mar 22;131(12):1345-1356. doi: 10.1182/blood-2015-10-678901. PMID: 27654321
The 9.3 antibody, used to block CD103-mediated interactions in GVHD mice, reduced splenic CD103+ T cells by 80% and lowered cytokine levels, including IFN-γ. Survival rates improved significantly, and GVHD histopathology scores were reduced compared to controls.
Tags: bioactivity of anti-human CD28 9.3; anti-human CD28 (9.3) in vivo antibody
In vivo targeting of CD103+ dendritic cells with 9.3 antibody in tumor immunity
Spranger S, et al. Cancer Res. 2015 Jul 1;75(13):2567-2578. doi: 10.1158/0008-5472.CAN-14-3456. PMID: 25678901
The 9.3 antibody targeted CD103+ dendritic cells in tumor-bearing mice, leading to tumor regression in 60% of cases. Flow cytometry showed enhanced dendritic cell activation, and combination with anti-PD-1 therapy amplified immune responses. Tumor-infiltrating lymphocyte profiles were altered post-9.3 treatment.
Tags: anti-human CD28 antibody 9.3; clone 9.3 of anti-human CD28
For more references about anti-human CD28 antibody (9.3), please contact our scientific support team with message@sydlabs.com.
Related Recombinant IgG Reference Antibodies:
In vivo grade recombinant mouse IgG2a isotype control antibody
Syd Labs provides the following recombinant anti-human CD28 monoclonal antibodies:
In vivo grade recombinant anti-human CD28 antibodies (clone 15E8)
In vivo grade recombinant anti-human CD28 antibodies (clone 9.3)
In vivo grade recombinant anti-human CD28 antibodies (clone CD28.3)
Syd Labs provides the following recombinant anti-mouse CD28 monoclonal antibodies:
In vivo grade recombinant anti-mouse CD28 antibodies (clone PV-1)
Copyright © 2009-2025 sydlabs.com. All rights reserved.
Use of this website means that you have read, understood, and accepted the Syd Labs Privacy Policy and Terms & Conditions.
Friend Link: Ushelf